2020年10月30日07:00 GMT
Agreement supports strategy of focusing on newer medicines in main therapy areas
澳门在线赌城娱乐 has agreed to sell the commercial rights to Atac和 (c和esartan cilexetil) 和 Atac和 + (a fixed-dose combination of c和esartan cilexetil 和 hydrochlorothiazide) in around 70 countries globally to Cheplapharm Arzneimittel GmbH (Cheplapharm).
Atac和 is a prescription medicine approved for the treatment of heart failure (HF) 和 hypertension. Atac和 + is approved for the treatment of hypertension.
路德浮标, 执行副总裁, 澳门第一赌城在线娱乐 Business Unit, said: “This agreement forms part of our strategy to carefully manage the mature medicines, enabling reinvestment in our main therapy areas to bring innovative new medicines to patients. Cheplapharm previously acquired the rights to Atac和 在欧洲 和 will now ensure continued patient access to this important established medicine in additional countries across the globe.”
澳门在线赌城娱乐 will continue to manufacture 和 supply Atac和 和 Atac和 + 和 will continue to commercialise the medicine during a three-year transition period. The agreement covers a total of more than 70 countries.1
金融方面的考虑
Cheplapharm will pay 澳门在线赌城娱乐 a total of $400m in non-contingent consideration, of which the present value will be recognised as Other Operating Income upon completion of the transaction, anticipated during the fourth quarter of 2020. The divestment will not impact the Company’s financial guidance for 2020.
Of the $400m consideration, $250m will be payable on completion 和 the remainder in the first half of 2021.
Pursuant to London Stock Exchange listing rule 10.4.1R (notification of class 2 transactions), in 2019, Atac和 和 Atac和 + generated sales of $148m 和 profit before tax of $89m in the countries covered by the agreement. The gross book value of assets subject to the divestment as at 31 December 2019 was nil. The consideration will be paid in cash 和 the proceeds used for general corporate purposes.
Atac和
Atac和 (c和esartan cilexetil) is a selective, AT1 subtype angiotensin II receptor antagonist that is indicated for the management of hypertension in adults 和 children/adolescents, 以及成人的心衰. Atac和 + is indicated for the management of hypertension when c和esartan or hydrochlorothiazide monotherapy is not sufficiently effective. Atac和 was developed in collaboration with Takeda Pharmaceutical Company Limited. Each company held the exclusive rights to the medicine in certain countries; in other countries, Atac和 是co-marketed.
澳门在线赌城娱乐
澳门在线赌城娱乐 (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development 和 commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas - 肿瘤学, 心血管, 肾 & Metabolism, 和 呼吸 & 免疫学. 总部设在剑桥, UK, 澳门在线赌城娱乐 operates in over 100 countries 和 its innovative medicines are used by millions of patients worldwide. 请访问 澳门在线赌城娱乐.com 和 follow the Company on 推特 @澳门在线赌城娱乐.
联系人
For details on how to contact the 投资者关系 Team, please click 在这里. 对于“媒体联系人”，单击 在这里.
参考文献
1. 国家包括:, 阿根廷, 阿鲁巴岛, 澳大利亚, 巴哈马群岛, 巴林, 百慕大, 巴巴多斯, 贝宁, 博茨瓦纳, 巴西, 文莱达鲁萨兰国, 布吉纳法索, 喀麦隆, 加拿大, 开曼群岛, 智利, 哥伦比亚, 刚果, 哥斯达黎加, 库拉索岛, 科特迪瓦, 吉布提, 多米尼加共和国, 厄瓜多尔, 埃及, 萨尔瓦多, 加蓬, 乔治亚州, 加纳, 危地马拉, 几内亚, 海地, 洪都拉斯, 伊拉克, 牙买加, 约旦, 肯尼亚, 大韩民国, 科威特, 黎巴嫩, 利比亚, 马达加斯加, 马来西亚, 马里, 毛利塔尼亚, 毛里求斯, 墨西哥, 纳米比亚, 新西兰, 尼加拉瓜, 尼日尔, 尼日利亚, 阿曼, 巴勒斯坦, 巴拿马, 秘鲁, 卡塔尔, 俄罗斯联邦, 沙特阿拉伯, 塞内加尔, 新加坡, 南非, 斯里兰卡, 苏丹, 多哥, 特立尼达和多巴哥, 突尼斯, 火鸡, 乌克兰, 阿拉伯联合酋长国, 乌拉圭, 也门.
艾德里安·坎普
公司秘书
澳门在线赌城娱乐